Quaise Energy and Nevada Gold Mines Partner on Deep Geothermal Pilot Plant to Decarbonize Mining
NGM Bio Announces Closing of Tender Offer
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
3 Best Penny Stocks To Buy Before November According To Insiders
After Plunging 76.6% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
NGM's eye drug fails in a Phase 2 clinical trial
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Executives Buy Over $15M Of 3 Stocks
NGM Bio to Participate in Upcoming Investor Conferences
5 Graham's Lost Formula Biotech Stocks to Consider for May
NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
NGM Bio to Participate in Upcoming Investor Conferences
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
NGM Bio to Participate in Upcoming Investor Conferences
NGM Bio to Participate in Upcoming Investor Conferences
Is Good News Enough for You to Buy NGM on the Dip?
NGM Bio Presents Preliminary Data From NGM120 Solid Tumor Trial
Raymond James Upgraded This Biopharma Stock And Sees 44% Upside
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research